|
|
Article: New therapeutics highlighted at ARVO
- Article from:
- Ophthalmology Times
- Article date:
- August 1, 2009
- Author:
CopyrightCopyright Advanstar Communications, Inc. Aug 1, 2009. Provided by ProQuest LLC. (Hide copyright information)
|
An overview
Studies show improvement in patients with AMD, dry eye, lid margin disease, and other conditions
This year's annual gathering for the Association for Research in Vision and Ophthalmology (ARVO) meeting in Fort Lauderdale, FL1 produced an array of posters and sessions on all the therapeutic areas. In this review, we'll take a look at the presentations that we considered to be highlights of ARVO 2009.
Retina research
Regeneran continues its work on a fusion protein (VEGF Trap-Eye) that binds to all VEGF-A isotbrms and PIGF. Results from the 12-month phase II study (n = 157) in neovascular age-related macular degeneration demonstrated that the drug lowers central retinal thickness, ...